Analyst Activity – Leerink Swann Initiates Coverage On Arena Pharmaceuticals (NASDAQ:ARNA) With a Outperform

13

Analyst Ratings For Arena Pharmaceuticals (NASDAQ:ARNA)

Today, Leerink Swann initiated coverage on Arena Pharmaceuticals (NASDAQ:ARNA) with a Outperform with a price target of $5.00.

There are 2 hold ratings, 3 buy ratings on the stock.

The current consensus rating on Arena Pharmaceuticals (NASDAQ:ARNA) is Buy (Score: 2.60) with a consensus target price of $5.50 per share, a potential 313.53% upside.

Some recent analyst ratings include

  • 5/19/2017-Leerink Swann initiated coverage with a Outperform rating.
  • 3/16/2017-FBR & Co Reiterated Rating of Outperform.
  • 1/7/2017-Needham & Company LLC Reiterated Rating of Hold.
  • 8/10/2016-Jefferies Group LLC Reiterated Rating of Buy.
  • 8/8/2016-JPMorgan Chase & Co. Reiterated Rating of Hold.
  • 5/10/2016-Wells Fargo & Co Reiterated Rating of Hold.
  • 3/2/2016-Piper Jaffray Companies Reiterated Rating of Buy.

Dividend information for Arena Pharmaceuticals (NASDAQ:ARNA)

.
Recent Insider Trading Activity For Arena Pharmaceuticals (NASDAQ:ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) has insider ownership of 2.14% and institutional ownership of 48.99%.

  • On 5/12/2017 Amit Munshi, Insider, bought 25,000 with an average share price of $1.19 per share and the total transaction amounting to $29,750.00. View SEC Filing
  • On 4/26/2017 Amit Munshi, Insider, bought 50,000 with an average share price of $1.41 per share and the total transaction amounting to $70,500.00. View SEC Filing
  • On 6/13/2016 Christine Anna White, Director, sold 18,728 with an average share price of $1.99 per share and the total transaction amounting to $37,268.72. View SEC Filing
  • On 3/30/2015 Randall E Woods, Director, sold 76,268 with an average share price of $4.49 per share and the total transaction amounting to $342,443.32. View SEC Filing
  • On 3/17/2015 Steven W Spector, EVP, sold 70,000 with an average share price of $5.00 per share and the total transaction amounting to $350,000.00. View SEC Filing
  • On 1/8/2015 Steven W Spector, EVP, sold 45,000 with an average share price of $6.26 per share and the total transaction amounting to $281,700.00. View SEC Filing
  • On 1/7/2015 William R Shanahan Jr, SVP, sold 50,000 with an average share price of $5.49 per share and the total transaction amounting to $274,500.00. View SEC Filing

About Arena Pharmaceuticals (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company’s drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company’s drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company’s programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Recent Trading Activity for Arena Pharmaceuticals (NASDAQ:ARNA)
Shares of Arena Pharmaceuticals closed the previous trading session at 1.33 up +0.18 15.65% with 7,013,464 shares trading hands.

An ad to help with our costs